Imed Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 15-12-2024
- Paid Up Capital ₹ 8.99 M
as on 15-12-2024
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 8.75 Cr
as on 15-12-2024
- Revenue -30.18%
(FY 2015)
- Profit -141584.03%
(FY 2015)
- Ebitda -588.60%
(FY 2015)
- Net Worth -500.07%
(FY 2015)
- Total Assets -65.06%
(FY 2015)
About Imed Pharmaceuticals (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 8.99 M.
The company currently has active open charges totaling ₹8.75 Cr.
Gayathri Bhavikatti and Narasappa Bhavikatti serve as directors at the Company.
- CIN/LLPIN
U24200KA2008PTC047159
- Company No.
047159
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2008
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Dharwad, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Imed Pharmaceuticals (India) Private Limited offer?
Imed Pharmaceuticals (India) Private Limited offers a wide range of products and services, including Cough Syrup.
Who are the key members and board of directors at Imed Pharmaceuticals (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gayathri Bhavikatti  | Director | 15-Jul-2008 | Current |
| Narasappa Bhavikatti | Director | 15-Jul-2008 | Current |
Financial Performance and Corporate Structure Insights of Imed Pharmaceuticals (India).
Imed Pharmaceuticals (India) Private Limited, for the financial year ended 2015, experienced significant reduction in revenue, with a 30.18% decrease. The company also saw a substantial fall in profitability, with a 141584.03% decrease in profit. The company's net worth observed a substantial decline by a decrease of 500.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Imed Pharmaceuticals (India)?
In 2015, Imed Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 20 Dec 2012 | ₹3.75 Cr | Open |
Krishnakumar G. Agrawal On Behalf Of Kare Labs Private Limited Creation Date: 21 Aug 2012 | ₹5.00 Cr | Open |
How Many Employees Work at Imed Pharmaceuticals (India)?
Imed Pharmaceuticals (India) has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Imed Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Imed Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
